Saxenda is approved for: Adults Adults with obesity (BMI of 30 kg/m or greater) Adults who are overweight (BMI of 27 kg/m or greater) and have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol Children aged 12 and older Adolescents with obesity who weigh more than 60 kg (132 pounds) Limitations of use Saxenda should not be used together with other medicines that contain liraglutide, such as Victoza, or with any other GLP-1 receptor agonist, such as Ozempic, Wegovy, or Trulicity The safety and effectiveness of Saxenda in children aged 12 to 17 years who have type 2 diabetes have not been established
Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
Therefore, these results demonstrate that both VPA exposure and LipRSV treatment provoke distinct regional alterations in the antioxidant system
When youre ready to go to the next step, remove the inner and outer needle cap
Remember, youre receiving vitamins not drugs